Sponsors had an exceptional second half of 2019 in obtaining novel drug and therapeutic biologic approvals from the US Food and Drug Administration after struggling during the first six months. And the strong finish resulted in the second-highest novel approval count in a contemporary calendar year.
The FDA's Center for Drug Evaluation and Research (CDER) cleared 35 new molecular entities (NMEs) and novel biologic entities (NBEs)...






